<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">Cerebral vasospasm</z:e> and delayed <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> account for significant morbidity and mortality after aneurysmal <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>While most patients are managed with triple-H therapy, endovascular treatments have been used when triple-H treatment cannot be used or is ineffective </plain></SENT>
<SENT sid="2" pm="."><plain>An electronic literature search was conducted to identify English language articles published through October 2010 that addressed endovascular management of vasospasm </plain></SENT>
<SENT sid="3" pm="."><plain>A total of 49 articles were identified, addressing endovascular treatment timing, intra-arterial treatments, and balloon angioplasty </plain></SENT>
<SENT sid="4" pm="."><plain>Most of the available studies investigated intra-arterial papaverine or balloon angioplasty </plain></SENT>
<SENT sid="5" pm="."><plain>Both have generally been shown to successfully treat vasospasm and improve neurological condition, with no clear benefit from one treatment compared with another </plain></SENT>
<SENT sid="6" pm="."><plain>There are reports of complications with both therapies including vessel rupture during angioplasty, intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo>, and possible neurotoxicity associated with papaverine </plain></SENT>
<SENT sid="7" pm="."><plain>Limited data are available evaluating nicardipine or <z:chebi fb="1" ids="9948">verapamil</z:chebi>, with positive benefits reported with nicardipine and inconsistent benefits with <z:chebi fb="1" ids="9948">verapamil</z:chebi> </plain></SENT>
</text></document>